Virax Biolabs Group Ltd (VRAX) stock
VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
$0.45−0.16 (-26.87%)
Close on Nov 16, 2026Market cap $259.49KP/E –Yield –
Virax Biolabs total assets
Total assets on the balance sheet at the end of each period.
Virax Biolabs's total assets was $8.32M at Mar 31, 2026. For fiscal 2026 it was $8.32M, up 29.5% from the year before. The highest annual figure on record is $9.81M in fiscal 2023.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $8.32M | +29.5% |
| FY2025 | Mar 31, 2025 | $6.43M | +17.2% |
| FY2024 | Mar 31, 2024 | $5.48M | -44.1% |
| FY2023 | Mar 31, 2023 | $9.81M | +20046.2% |
| FY2022 | Mar 31, 2022 | $48.71K | +22.9% |
| FY2021 | Mar 31, 2021 | $39.62K | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $8.32M | +16991.9% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $6.43M | +16121.0% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $5.48M | – |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $9.81M | – |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $48.71K | – |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $39.62K | – |
See a number that looks wrong?